GBA2 and nasopharyngeal carcinoma: It should be noted there is no report that Miglustat (N-butyldeoxynojirimycin), an orphan drug for type 1 GD disease or NPC, which inhibits GBA2 activity as well as glucosylceramide synthase, induced parkinsonism [37, 43].